Results 51 to 60 of about 6,090,817 (193)

8176 An Unusual Case of Thyroid Eye Disease (TED) Occurring in Autoimmune Hypothyroidism [PDF]

J Endocr Soc
Abstract Disclosure: K. Prasongdee: None. C.M. Tessier: None. Background: It is unusual for TED to present in patients with autoimmune thyroid disease who are euthyroid or hypothyroid. Clinician recognition of this rare presentation is important in ensuring proper treatment and improving patient outcomes. Clinical Case:Our
Prasongdee, K, Tessier, C M
europepmc   +2 more sources

6814 Durability of Teprotumumab for the Treatment of Thyroid Eye Disease (TED) in Clinical Trials [PDF]

J Endocr Soc
Abstract Disclosure: G.J. Kahaly: Consulting Fee; Self; Amgen Inc. Research Investigator; Self; Amgen Inc. P.S. Subramanian: Consulting Fee; Self; Amgen Inc. Research Investigator; Self; Amgen Inc. E. Conrad: Employee; Self; Amgen Inc. Stock Owner; Self; Amgen Inc. R.J. Holt: Employee; Self; Amgen Inc. Stock Owner; Self; Amgen Inc.
Kahaly, George J, Subramanian, Prem S, Conrad, Elizabeth, Holt, Robert J, Smith, Terry J   +4 more
europepmc   +2 more sources

FRI546 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED): Pharmacodynamic Responses In Healthy Volunteers And Patients With Active TED [PDF]

J Endocr Soc, 2023
Abstract Disclosure: K. Foster: Employee; Self; Viridian Therapeutics Inc. B.A. Dickinson: Employee; Self; Viridian Therapeutics Inc. R.M. Summerfelt: Employee; Self; Viridian Therapeutics Inc. A. She: Employee; Self; Viridian Therapeutics Inc. V. Bedian: Employee; Self; Viridian Therapeutics Inc. B.
Foster, Kelly, Dickinson, Brent A, Summerfelt, Rochelle M, She, Angela, Bedian, Vahe, Katz, Barrett   +5 more
europepmc   +2 more sources

Transcriptomic and Neuroimaging Decoding of Brain‐Immune Crosstalk in Thyroid Eye Disease

Advanced Science, Volume 13, Issue 27, 13 May 2026.
This study employed an imaging transcriptomics framework integrating resting‐state fMRI with Allen Human Brain Atlas transcriptomic data, coupled with peripheral blood RNA sequencing, to decode brain‐immune crosstalk in thyroid eye disease. Frontal, parietal, subcortical, and brainstem regions were identified as key neuroimmune‐ vulnerable regions ...
Haiyang Zhang, Yuting Liu, Shufan Jiang, Zilin Fang, Mengda Jiang, Xiaofeng Tao, Tianyi Zhu, Jipeng Li, Sijie Fang, Xuefei Song, Yinwei Li, Jing Sun, Chuanjun Tong, Zhengrun Gao, Huifang Zhou, Xianqun Fan   +15 more
wiley   +1 more source

Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics

Advanced Science, Volume 13, Issue 18, 27 March 2026.
This review provides a systematic comparison of extracellular vesicles (EVs) from both mammalian and plant sources in the context of autoimmune diseases. It highlights their emerging roles as precision biomarkers and engineered therapeutic platforms.
Yufei Wu, Huiyuan Ma, Tinghui Zhu, Shuwei Huang, Manxi Lu, Qiong Wang, Zai‐Long Chi   +6 more
wiley   +1 more source

Orbital lymphocyte populations in three states of thyroid eye disease

American Journal of Ophthalmology Case Reports, 2023
Purpose: We report histopathologic orbital tissue analysis from three patients with thyroid eye disease (TED) – active, chronic, and post-teprotumumab to better characterize orbital cellular populations in these varying states of TED.
Shane M. Griffin, Rona Z. Silkiss
doaj   +1 more source

Clinical Profile of Thyroid Eye Disease and Factors Predictive of Disease Severity in Chennai District of Tamil Nadu

TNOA Journal of Ophthalmic Science and Research
Background: Thyroid eye disease (TED) is a possibly sightthreatening ocular disease generally occurring in the patients diagnosed with hyperthyroidism.
Mohamed Uwais Ulla, Pratheebadevi Nivean, Mohamed Abrar, Nivean Madhivanan   +3 more
doaj   +1 more source

Absent Bell’s phenomenon in patients with thyroid eye disease

BMC Ophthalmology, 2021
Background To investigate the incidence of absent Bell’s phenomenon (BP) and the relationship between absent BP and inferior rectus muscle hypertrophy and other clinical features in patients with thyroid eye disease (TED). Methods A total of 104 patients
Hyun Woo Chung, Hwa Lee, Sehyun Baek
doaj   +1 more source

Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 1, February 2026.
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar, Pedro Lança Gomes, Gaurav Jategaonkar, Michael J. Marino, Amar Miglani, Devyani Lal   +5 more
wiley   +1 more source

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset, Roy Miodini Nilsen, Kristian Løvås, Kathrine Halsøy, Håkon Reikvam, Ann‐Elin Meling Stokland, Grethe Åstrøm Ueland, Anette S. B. Wolff, Hans Christian D. Aass, Sjur Reppe, Eystein Sverre Husebye, Eyvind Rødahl, Tor Paaske Utheim, Hans Olav Ueland   +13 more
wiley   +1 more source